Development of a tool for effective comparisons of breast cancer survival between hospitals

Development and validation of a risk-adjustment model for breast cancer survival - a retrospective registry-based study on Swedish breast cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN69229101

Enrollment

35000

Registered

2022-11-14

Start date

2007-01-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Malignant neoplasm of breast

Interventions

Population: A Swedish database (i.e. BcBaSe 3.0) has been constructed linking the Swedish National Registry for Breast Cancer (NCBR) with several other Swedish government registries. The database cont

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older 2. Breast cancer diagnosis between 01/01/2007 and 31/12/2014 3. Treated for breast cancer in Sweden 4. Stage I-III at diagnosis (no distant metastasis)

Exclusion criteria

Exclusion criteria: De novo (or within 3 months of diagnosis) metastatic breast cancer (stage IV breast cancer)

Design outcomes

Primary

Measure	Time frame
Overall model performance, discrimination and calibration of a model on 5-year relative survival	—

Secondary

Measure	Time frame
Overall model performance, discrimination and calibration for models on: 1. 5-year overall survival 2. 5-year disease-free survival 3. 10-year relative survival 4. 10-year overall survival 5. 10-year disease-free survival 6. 5-year relative survival of patients with triple-negative breast cancer based on this subgroup of patients 7. 5-year relative survival of patients with ER-positive breast cancer based on this subgroup of patients 8. 5-year relative survival of patients with HER2-positive breast cancer based on this subgroup of patients 9. 5-year observed survival of patients with triple-negative breast cancer based on this subgroup of patients 10. 5-year observed survival of patients with ER-positive breast cancer based on this subgroup of patients 11. 5-year observed survival of patients with HER2-positive breast cancer based on this subgroup of patients 12. 5-year disease-free survival of patients with triple-negative breast cancer based on this subgroup of patients 13. 5-year disease-free survival of patients with ER-positive breast cancer based on this subgroup of patients 14. 5-year disease-free survival of patients with HER2-positive breast cancer based on this subgroup of patients 15. 10-year relative survival of patients with triple-negative breast cancer based on this subgroup of patients (under-powered) 16. 10-year relative survival of patients with ER-positive breast cancer based on this subgroup of patients 17. 10-year relative survival of patients with HER2-positive breast cancer based on this subgroup of patients (under-powered) 18. 10-year observed survival of patients with triple-negative breast cancer based on this subgroup of patients (under-powered) 19. 10-year observed survival of patients with ER-positive breast cancer based on this subgroup of patients 20. 10-year observed survival of patients with HER2-positive breast cancer based on this subgroup of patients (under-powered) 21. 10-year disease-free survival of patients with triple-nega	—

Measure

Time frame

Overall model performance, discrimination and calibration for models on: 1. 5-year overall survival 2. 5-year disease-free survival 3. 10-year relative survival 4. 10-year overall survival 5. 10-year disease-free survival 6. 5-year relative survival of patients with triple-negative breast cancer based on this subgroup of patients 7. 5-year relative survival of patients with ER-positive breast cancer based on this subgroup of patients 8. 5-year relative survival of patients with HER2-positive breast cancer based on this subgroup of patients 9. 5-year observed survival of patients with triple-negative breast cancer based on this subgroup of patients 10. 5-year observed survival of patients with ER-positive breast cancer based on this subgroup of patients 11. 5-year observed survival of patients with HER2-positive breast cancer based on this subgroup of patients 12. 5-year disease-free survival of patients with triple-negative breast cancer based on this subgroup of patients 13. 5-year disease-free survival of patients with ER-positive breast cancer based on this subgroup of patients 14. 5-year disease-free survival of patients with HER2-positive breast cancer based on this subgroup of patients 15. 10-year relative survival of patients with triple-negative breast cancer based on this subgroup of patients (under-powered) 16. 10-year relative survival of patients with ER-positive breast cancer based on this subgroup of patients 17. 10-year relative survival of patients with HER2-positive breast cancer based on this subgroup of patients (under-powered) 18. 10-year observed survival of patients with triple-negative breast cancer based on this subgroup of patients (under-powered) 19. 10-year observed survival of patients with ER-positive breast cancer based on this subgroup of patients 20. 10-year observed survival of patients with HER2-positive breast cancer based on this subgroup of patients (under-powered) 21. 10-year disease-free survival of patients with triple-nega

—

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026